Tert-Butylamine

Tert-Butylamine

SCHEMBL760575

CC(C)(C)N.N=C=O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACEIDH1

The experimentally established mechanism targets of Tert-Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2439671 0.82
SCHEMBL223546 0.82
SCHEMBL28146203 0.79
Methylamine SCHEMBL9483619 0.77
Chloromethane SCHEMBL17457033 0.77
Tert-Butanol SCHEMBL11746210 0.75 ALDH1A1 (0.35)
Trichloroethane SCHEMBL27829168 0.75
Methylamine SCHEMBL7552685 0.73
Ethane SCHEMBL6302671 0.71 TSHR (0.42)
Ethane SCHEMBL690547 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399473-B2 Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease Merck, Sharp & Dohme, Corp. (US) 2013-03-19 US disclosed
EP-2073635-B1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2012-03-21 EP disclosed
US-20100029701-A1 MACROCYCLIC SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME LLC 2010-02-04 US disclosed